SPECIAL REPORT
7TH JOINT ECTRIMS-ACTRIMS MEETING – October 25-28, 2017
Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab Read More
Latest News
Vortioxetine: Improved work productivity in adults with major depression
December 13, 2017SPECIAL REPORT
Comment by Dr. Pratap Chokka, Edmonton, Alberta
Antidepressant therapies have traditionally been evaluated for their effect on symptoms of depression and anxiety. However, symptomatic improvements may not result in functional gains in areas such as work performance and productivity, activities of daily living and quality of life. In the latest iteration of the Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder (MDD), functional recovery was recognized as a priority in the treatment of MDD in both the acute and maintenance phases of the disease (Lam et al. Ann Clin Psychiatry 2015;27:142-149). The group concluded that there was a need for evidence-based interventions that demonstrated an improvement in patient functioning. Read More
Cladribine tablets (Mavenclad) approved in Canada for RRMS
December 4, 2017Health Canada has approved cladribine tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS), to reduce the frequency of clinical exacerbations and delay the progression of disability. The drug, marketed as Mavenclad, may be used for newly-diagnosed patients, but is generally recommended in MS patients with an inadequate response or poor tolerability to a prior MS therapy. Read More
Cladribine tablets – Updated efficacy and safety results
November 28, 2017Cladribine tablets, a novel intermittent immunosuppressant expected soon in North America, has been shown to be highly efficacious in reducing annualized relapse rates (ARR) and disability progression over a sustained period, according to the most recent data. Read More